Logo image of INMD

INMODE LTD (INMD) Stock Fundamental Analysis

NASDAQ:INMD - Nasdaq - IL0011595993 - Common Stock - Currency: USD

16.25  +0.12 (+0.74%)

Fundamental Rating

7

Taking everything into account, INMD scores 7 out of 10 in our fundamental rating. INMD was compared to 191 industry peers in the Health Care Equipment & Supplies industry. INMD gets an excellent profitability rating and is at the same time showing great financial health properties. INMD is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make INMD suitable for value and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

INMD had positive earnings in the past year.
INMD had a positive operating cash flow in the past year.
INMD had positive earnings in each of the past 5 years.
Each year in the past 5 years INMD had a positive operating cash flow.
INMD Yearly Net Income VS EBIT VS OCF VS FCFINMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

With an excellent Return On Assets value of 23.07%, INMD belongs to the best of the industry, outperforming 98.43% of the companies in the same industry.
With an excellent Return On Equity value of 25.76%, INMD belongs to the best of the industry, outperforming 96.34% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 14.32%, INMD belongs to the top of the industry, outperforming 95.81% of the companies in the same industry.
INMD had an Average Return On Invested Capital over the past 3 years of 22.89%. This is significantly above the industry average of 7.68%.
The 3 year average ROIC (22.89%) for INMD is well above the current ROIC(14.32%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 23.07%
ROE 25.76%
ROIC 14.32%
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
INMD Yearly ROA, ROE, ROICINMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

With an excellent Profit Margin value of 45.91%, INMD belongs to the best of the industry, outperforming 97.91% of the companies in the same industry.
INMD's Profit Margin has improved in the last couple of years.
The Operating Margin of INMD (28.50%) is better than 96.86% of its industry peers.
In the last couple of years the Operating Margin of INMD has declined.
Looking at the Gross Margin, with a value of 80.31%, INMD belongs to the top of the industry, outperforming 93.19% of the companies in the same industry.
In the last couple of years the Gross Margin of INMD has declined.
Industry RankSector Rank
OM 28.5%
PM (TTM) 45.91%
GM 80.31%
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
INMD Yearly Profit, Operating, Gross MarginsINMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

9

2. Health

2.1 Basic Checks

INMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, INMD has less shares outstanding
The number of shares outstanding for INMD has been increased compared to 5 years ago.
INMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INMD Yearly Shares OutstandingINMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
INMD Yearly Total Debt VS Total AssetsINMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

INMD has an Altman-Z score of 11.54. This indicates that INMD is financially healthy and has little risk of bankruptcy at the moment.
INMD has a better Altman-Z score (11.54) than 92.67% of its industry peers.
INMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.54
ROIC/WACC1.59
WACC9.03%
INMD Yearly LT Debt VS Equity VS FCFINMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

INMD has a Current Ratio of 10.23. This indicates that INMD is financially healthy and has no problem in meeting its short term obligations.
INMD has a better Current ratio (10.23) than 92.67% of its industry peers.
INMD has a Quick Ratio of 9.38. This indicates that INMD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.38, INMD belongs to the top of the industry, outperforming 92.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.23
Quick Ratio 9.38
INMD Yearly Current Assets VS Current LiabilitesINMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for INMD have decreased strongly by -30.47% in the last year.
INMD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 22.97% yearly.
INMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.77%.
INMD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.35% yearly.
EPS 1Y (TTM)-30.47%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%-40.85%
Revenue 1Y (TTM)-19.77%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%-22.82%

3.2 Future

Based on estimates for the next years, INMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.32% on average per year.
The Revenue is expected to grow by 3.12% on average over the next years.
EPS Next Y10.39%
EPS Next 2Y9.9%
EPS Next 3Y9.32%
EPS Next 5YN/A
Revenue Next Year-2.33%
Revenue Next 2Y1.5%
Revenue Next 3Y3.12%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
INMD Yearly Revenue VS EstimatesINMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
INMD Yearly EPS VS EstimatesINMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2 2.5

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 9.13, which indicates a very decent valuation of INMD.
Compared to the rest of the industry, the Price/Earnings ratio of INMD indicates a rather cheap valuation: INMD is cheaper than 96.34% of the companies listed in the same industry.
INMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.92.
A Price/Forward Earnings ratio of 8.27 indicates a reasonable valuation of INMD.
97.38% of the companies in the same industry are more expensive than INMD, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.65, INMD is valued rather cheaply.
Industry RankSector Rank
PE 9.13
Fwd PE 8.27
INMD Price Earnings VS Forward Price EarningsINMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

98.43% of the companies in the same industry are more expensive than INMD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, INMD is valued cheaper than 98.43% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.36
EV/EBITDA 2.04
INMD Per share dataINMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
INMD has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.88
PEG (5Y)0.4
EPS Next 2Y9.9%
EPS Next 3Y9.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INMODE LTD

NASDAQ:INMD (4/25/2025, 3:58:09 PM)

16.25

+0.12 (+0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-04 2025-02-04/bmo
Earnings (Next)04-28 2025-04-28/bmo
Inst Owners65.62%
Inst Owner Change-0.05%
Ins Owners9.67%
Ins Owner ChangeN/A
Market Cap1.10B
Analysts78.46
Price Target21.76 (33.91%)
Short Float %10.89%
Short Ratio4.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.69%
Min EPS beat(2)-20.27%
Max EPS beat(2)8.88%
EPS beat(4)1
Avg EPS beat(4)-11.89%
Min EPS beat(4)-23.01%
Max EPS beat(4)8.88%
EPS beat(8)4
Avg EPS beat(8)-3.94%
EPS beat(12)8
Avg EPS beat(12)0.95%
EPS beat(16)12
Avg EPS beat(16)4.66%
Revenue beat(2)1
Avg Revenue beat(2)-4.71%
Min Revenue beat(2)-9.96%
Max Revenue beat(2)0.53%
Revenue beat(4)1
Avg Revenue beat(4)-10.36%
Min Revenue beat(4)-16.64%
Max Revenue beat(4)0.53%
Revenue beat(8)3
Avg Revenue beat(8)-5.88%
Revenue beat(12)7
Avg Revenue beat(12)-2.33%
Revenue beat(16)11
Avg Revenue beat(16)0.25%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-7.99%
EPS NQ rev (3m)-23.11%
EPS NY rev (1m)-0.74%
EPS NY rev (3m)-8.79%
Revenue NQ rev (1m)-4.82%
Revenue NQ rev (3m)-13.5%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)-6.28%
Valuation
Industry RankSector Rank
PE 9.13
Fwd PE 8.27
P/S 2.79
P/FCF 8.36
P/OCF 8.31
P/B 1.57
P/tB 1.57
EV/EBITDA 2.04
EPS(TTM)1.78
EY10.95%
EPS(NY)1.96
Fwd EY12.09%
FCF(TTM)1.94
FCFY11.97%
OCF(TTM)1.95
OCFY12.03%
SpS5.82
BVpS10.37
TBVpS10.37
PEG (NY)0.88
PEG (5Y)0.4
Profitability
Industry RankSector Rank
ROA 23.07%
ROE 25.76%
ROCE 15.72%
ROIC 14.32%
ROICexc 85.89%
ROICexgc 85.89%
OM 28.5%
PM (TTM) 45.91%
GM 80.31%
FCFM 33.43%
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
ROICexc(3y)532.49%
ROICexc(5y)5023.19%
ROICexgc(3y)532.49%
ROICexgc(5y)5023.19%
ROCE(3y)25.13%
ROCE(5y)28.51%
ROICexcg growth 3Y-60.68%
ROICexcg growth 5YN/A
ROICexc growth 3Y-60.68%
ROICexc growth 5YN/A
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
F-Score5
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 91.9%
Cap/Sales 0.17%
Interest Coverage 250
Cash Conversion 117.13%
Profit Quality 72.81%
Current Ratio 10.23
Quick Ratio 9.38
Altman-Z 11.54
F-Score5
WACC9.03%
ROIC/WACC1.59
Cap/Depr(3y)144.54%
Cap/Depr(5y)147.73%
Cap/Sales(3y)0.22%
Cap/Sales(5y)0.23%
Profit Quality(3y)91.09%
Profit Quality(5y)96.73%
High Growth Momentum
Growth
EPS 1Y (TTM)-30.47%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%-40.85%
EPS Next Y10.39%
EPS Next 2Y9.9%
EPS Next 3Y9.32%
EPS Next 5YN/A
Revenue 1Y (TTM)-19.77%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%-22.82%
Revenue Next Year-2.33%
Revenue Next 2Y1.5%
Revenue Next 3Y3.12%
Revenue Next 5YN/A
EBIT growth 1Y-42.48%
EBIT growth 3Y-12.42%
EBIT growth 5Y13.55%
EBIT Next Year-11.61%
EBIT Next 3Y1.62%
EBIT Next 5YN/A
FCF growth 1Y-25.05%
FCF growth 3Y-8.8%
FCF growth 5Y16.5%
OCF growth 1Y-24.97%
OCF growth 3Y-8.8%
OCF growth 5Y16.36%